Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]-2-propanol
Purity: ≥98%
Formula Markup: C19H17F6N7O
Formula Weight: 473.4
CAS Number: 1446502-11-9
Notes: Enasidenib is an inhibitor of mutant isocitrate dehydrogenase 2 (IDH2; IC50 = 0.1 µM for IDH2 R140Q).{33575} It is selective for IDH2 R140Q over wild-type IDH2, wild-type IDH1, and IDH1 R132H (IC50s = 1.8, 0.45, and 48.4 µM, respectively). Enasidenib (0.1, 1, and 5 µM) inhibits production of D-2-hydroxyglutarate (Item No. 11605) and induces differentiation in primary acute myeloid leukemia (AML) cells expressing IDH2 R140Q. It increases survival in a patient-derived xenograft (PDX) mouse model when administered at doses of 5, 15, and 45 mg/kg. Formulations containing enasidenib have been used in the treatment of AML.
English
Deutsch
